<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38793559</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>25</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Caboxamycin Inhibits Heart Inflammation in a Coxsackievirus B3-Induced Myocarditis Mouse Model.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">677</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16050677</ELocationID><Abstract><AbstractText>Coxsackievirus B3 (CVB3) is a positive single-strand RNA genome virus which belongs to the enterovirus genus in the picornavirus family, like poliovirus. It is one of the most prevalent pathogens that cause myocarditis and pancreatitis in humans. However, a suitable therapeutic medication and vaccination have yet to be discovered. Caboxamycin, a benzoxazole antibiotic isolated from the culture broth of the marine strain <i>Streptomyces</i> sp., SC0774, showed an antiviral effect in CVB3-infected HeLa cells and a CVB3-induced myocarditis mouse model. Caboxamycin substantially decreased CVB3 VP1 production and cleavage of translation factor eIF4G1 from CVB3 infection. Virus-positive and -negative strand RNA was dramatically reduced by caboxamycin treatment. In addition, the cleavage of the pro-apoptotic molecules BAD, BAX, and caspase3 was significantly inhibited by caboxamycin treatment. In animal experiments, the survival rate of mice was improved following caboxamycin treatment. Moreover, caboxamycin treatment significantly decreased myocardial damage and inflammatory cell infiltration. Our study showed that caboxamycin dramatically suppressed cardiac inflammation and mouse death. This result suggests that caboxamycin may be suitable as a potential antiviral drug for CVB3.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hong-Gi</ForeName><Initials>HG</Initials><AffiliationInfo><Affiliation>Department of Biomedical Science, Jungwon University, Goesan-gun 28024, Chungbuk, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hillman</LastName><ForeName>Prima F</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Nanoscience, Ewha Womans University, Seoul 03760, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>You-Jeung</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Samsung Medical Center, 50 Irwon Dong, Gangnam-gu, Seoul 06351, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Ha-Eun</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Department of Biomedical Science, Jungwon University, Goesan-gun 28024, Chungbuk, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Byung-Kwan</ForeName><Initials>BK</Initials><Identifier Source="ORCID">0000-0003-3974-1175</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Science, Jungwon University, Goesan-gun 28024, Chungbuk, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nam</LastName><ForeName>Sang-Jip</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-0944-6565</Identifier><AffiliationInfo><Affiliation>Department of Chemistry and Nanoscience, Ewha Womans University, Seoul 03760, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NRF-2022R1F1A1063986</GrantID><Agency>National Research Foundation of Korea</Agency><Country /></Grant><Grant><GrantID>No.22203MFDS403-1</GrantID><Agency>Ministry of Food and Drug Safety</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="Y">Myocarditis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="Y">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="Y">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coxsackievirus B3</Keyword><Keyword MajorTopicYN="N">Streptomyces sp. SC0774</Keyword><Keyword MajorTopicYN="N">caboxamycin</Keyword><Keyword MajorTopicYN="N">myocarditis</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>25</Day><Hour>10</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>25</Day><Hour>10</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>25</Day><Hour>1</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38793559</ArticleId><ArticleId IdType="pmc">PMC11125614</ArticleId><ArticleId IdType="doi">10.3390/v16050677</ArticleId><ArticleId IdType="pii">v16050677</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huber S.A., Lodge P.A. Coxsackievirus B-3 myocarditis. Identification of different pathogenic mechanisms in DBA/2 and Balb/c mice. Am. J. Pathol. 1986;122:284–291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1888112</ArticleId><ArticleId IdType="pubmed">3004227</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman A.M., McNamara D. Myocarditis. N. Engl. J. Med. 2000;343:1388–1398. doi: 10.1056/NEJM200011093431908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200011093431908</ArticleId><ArticleId IdType="pubmed">11070105</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff J.F. Viral myocarditis. A review. Am. J. Pathol. 1980;101:425–484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1903609</ArticleId><ArticleId IdType="pubmed">6254364</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlton K.U. Myocarditis: An Intersection Between Genetic and Acquired Causes of Human Cardiomyopathy. J. Am. Coll. Cardiol. 2017;69:1666–1668. doi: 10.1016/j.jacc.2017.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2017.02.008</ArticleId><ArticleId IdType="pubmed">28359510</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B.M., Mulkey S.B., Campos J.M., DeBiasi R.L. Laboratory diagnosis of CNS infections in children due to emerging and re-emerging neurotropic viruses. Pediatr. Res. 2024;95:543–550. doi: 10.1038/s41390-023-02930-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41390-023-02930-6</ArticleId><ArticleId IdType="pubmed">38042947</ArticleId></ArticleIdList></Reference><Reference><Citation>Abzug M.J., Cloud G., Bradley J., Sanchez P.J., Romero J., Powell D., Lepow M., Mani C., Capparelli E.V., Blount S., et al. Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis. Pediatr. Infect. Dis. J. 2003;22:335–341. doi: 10.1097/01.inf.0000059765.92623.70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.inf.0000059765.92623.70</ArticleId><ArticleId IdType="pubmed">12690273</ArticleId></ArticleIdList></Reference><Reference><Citation>Setia A., Bhatia J., Bhattacharya S. An Overview of Acute Flaccid Myelitis. CNS Neurol. Disord. Drug Targets. 2022;21:774–794. doi: 10.2174/1871527320666211125101424.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527320666211125101424</ArticleId><ArticleId IdType="pubmed">34823462</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayak G., Bhuyan S.K., Bhuyan R., Sahu A., Kar D., Kuanar A. Global emergence of Enterovirus 71: A systematic review. Beni-Suef Univ. J. Basic Appl. Sci. 2022;11:78. doi: 10.1186/s43088-022-00258-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43088-022-00258-4</ArticleId><ArticleId IdType="pmc">PMC9188855</ArticleId><ArticleId IdType="pubmed">35730010</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G., Qi J., Chen Z., Xu X., Gao F., Lin D., Qian W., Liu H., Jiang H., Yan J., et al. Enterovirus 71 and coxsackievirus A16 3C proteases: Binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J. Virol. 2011;85:10319–10331. doi: 10.1128/JVI.00787-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00787-11</ArticleId><ArticleId IdType="pmc">PMC3196414</ArticleId><ArticleId IdType="pubmed">21795339</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z., Cai T.Z., Lu Y., Liu W.J., Cheng M.L., Ji Y.Q. Coxsackievirus B3 induces viral myocarditis by upregulating toll-like receptor 4 expression. Biochemistry. 2015;80:455–462. doi: 10.1134/S0006297915040094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S0006297915040094</ArticleId><ArticleId IdType="pubmed">25869363</ArticleId></ArticleIdList></Reference><Reference><Citation>Herskowitz A., Beisel K.W., Wolfgram L.J., Rose N.R. Coxsackievirus B3 murine myocarditis: Wide pathologic spectrum in genetically defined inbred strains. Hum. Pathol. 1985;16:671–673. doi: 10.1016/S0046-8177(85)80149-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0046-8177(85)80149-0</ArticleId><ArticleId IdType="pubmed">2989148</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong D., Yajima T., Lim B.K., Stenbit A., Dublin A., Dalton N.D., Summers-Torres D., Molkentin J.D., Duplain H., Wessely R., et al. Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy. Circulation. 2007;115:94–102. doi: 10.1161/CIRCULATIONAHA.106.631093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.106.631093</ArticleId><ArticleId IdType="pubmed">17190866</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim B.K., Peter A.K., Xiong D., Narezkina A., Yung A., Dalton N.D., Hwang K.K., Yajima T., Chen J., Knowlton K.U. Inhibition of Coxsackievirus-associated dystrophin cleavage prevents cardiomyopathy. J. Clin. Investig. 2013;123:5146–5151. doi: 10.1172/JCI66271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI66271</ArticleId><ArticleId IdType="pmc">PMC3859391</ArticleId><ArticleId IdType="pubmed">24200690</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun S.H., Lee W.G., Kim Y.C., Ju E.S., Lim B.K., Choi J.O., Kim D.K., Jeon E.S. Antiviral activity of coxsackievirus B3 3C protease inhibitor in experimental murine myocarditis. J. Infect. Dis. 2012;205:491–497. doi: 10.1093/infdis/jir745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jir745</ArticleId><ArticleId IdType="pubmed">22207647</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L.T., Hsu W.C., Lin C.C. Antiviral natural products and herbal medicines. J. Tradit. Complement. Med. 2014;4:24–35. doi: 10.4103/2225-4110.124335.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2225-4110.124335</ArticleId><ArticleId IdType="pmc">PMC4032839</ArticleId><ArticleId IdType="pubmed">24872930</ArticleId></ArticleIdList></Reference><Reference><Citation>Opavsky M.A., Martino T., Rabinovitch M., Penninger J., Richardson C., Petric M., Trinidad C., Butcher L., Chan J., Liu P.P. Enhanced ERK-1/2 activation in mice susceptible to coxsackievirus-induced myocarditis. J. Clin. Investig. 2002;109:1561–1569. doi: 10.1172/JCI13971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI13971</ArticleId><ArticleId IdType="pmc">PMC151008</ArticleId><ArticleId IdType="pubmed">12070303</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagoshi T., Matsui T., Aoyama T., Leri A., Anversa P., Li L., Ogawa W., del Monte F., Gwathmey J.K., Grazette L., et al. PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J. Clin. Investig. 2005;115:2128–2138. doi: 10.1172/JCI23073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI23073</ArticleId><ArticleId IdType="pmc">PMC1172227</ArticleId><ArticleId IdType="pubmed">16007268</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Zhu X., Xiong L., Ren J. Ablation of Akt2 prevents paraquat-induced myocardial mitochondrial injury and contractile dysfunction: Role of Nrf2. Toxicol. Lett. 2017;269:1–14. doi: 10.1016/j.toxlet.2017.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.toxlet.2017.01.009</ArticleId><ArticleId IdType="pubmed">28115273</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.G., Park J.H., Jeon E.S., Kim J.H., Lim B.K. Fructus Amomi Cardamomi Extract Inhibit Coxsackievirus-B3 Induced Myocarditis in Murine Myocarditis Model. J. Microbiol. Biotechnol. 2016;26:2012–2018. doi: 10.4014/jmb.1605.05056.</Citation><ArticleIdList><ArticleId IdType="doi">10.4014/jmb.1605.05056</ArticleId><ArticleId IdType="pubmed">27558433</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenical W., Jensen P.R. Developing a new resource for drug discovery: Marine actinomycete bacteria. Nat. Chem. Biol. 2006;2:666–673. doi: 10.1038/nchembio841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio841</ArticleId><ArticleId IdType="pubmed">17108984</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam K.S. Discovery of novel metabolites from marine actinomycetes. Curr. Opin. Microbiol. 2006;9:245–251. doi: 10.1016/j.mib.2006.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mib.2006.03.004</ArticleId><ArticleId IdType="pubmed">16675289</ArticleId></ArticleIdList></Reference><Reference><Citation>Losada A.A., Cano-Prieto C., Garcia-Salcedo R., Brana A.F., Mendez C., Salas J.A., Olano C. Caboxamycin biosynthesis pathway and identification of novel benzoxazoles produced by cross-talk in Streptomyces sp. NTK 937. Microb. Biotechnol. 2017;10:873–885. doi: 10.1111/1751-7915.12716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1751-7915.12716</ArticleId><ArticleId IdType="pmc">PMC5481532</ArticleId><ArticleId IdType="pubmed">28417606</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohmann C., Schneider K., Bruntner C., Irran E., Nicholson G., Bull A.T., Jones A.L., Brown R., Stach J.E., Goodfellow M., et al. Caboxamycin, a new antibiotic of the benzoxazole family produced by the deep-sea strain Streptomyces sp. NTK 937. J. Antibiot. 2009;62:99–104. doi: 10.1038/ja.2008.24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ja.2008.24</ArticleId><ArticleId IdType="pubmed">19198633</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong D., Lee G.H., Badorff C., Dorner A., Lee S., Wolf P., Knowlton K.U. Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: A genetic predisposition to viral heart disease. Nat. Med. 2002;8:872–877. doi: 10.1038/nm737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm737</ArticleId><ArticleId IdType="pubmed">12118246</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlton K.U., Jeon E.S., Berkley N., Wessely R., Huber S. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J. Virol. 1996;70:7811–7818. doi: 10.1128/jvi.70.11.7811-7818.1996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.70.11.7811-7818.1996</ArticleId><ArticleId IdType="pmc">PMC190851</ArticleId><ArticleId IdType="pubmed">8892902</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin H.H., Jeon E.S., Lim B.K. Macrophage-Specific Coxsackievirus and Adenovirus Receptor Deletion Enhances Macrophage M1 Polarity in CVB3-Induced Myocarditis. Int. J. Mol. Sci. 2023;24:5309. doi: 10.3390/ijms24065309.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24065309</ArticleId><ArticleId IdType="pmc">PMC10049483</ArticleId><ArticleId IdType="pubmed">36982385</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper L.T., Jr. Myocarditis. N. Engl. J. Med. 2009;360:1526–1538. doi: 10.1056/NEJMra0800028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra0800028</ArticleId><ArticleId IdType="pmc">PMC5814110</ArticleId><ArticleId IdType="pubmed">19357408</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairweather D., Yusung S., Frisancho S., Barrett M., Gatewood S., Steele R., Rose N.R. IL-12 receptor beta 1 and Toll-like receptor 4 increase IL-1 beta- and IL-18-associated myocarditis and coxsackievirus replication. J. Immunol. 2003;170:4731–4737. doi: 10.4049/jimmunol.170.9.4731.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.170.9.4731</ArticleId><ArticleId IdType="pubmed">12707353</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y.C., Yu C.K., Wang Y.F., Liu C.C., Su I.J., Lei H.Y. A murine oral enterovirus 71 infection model with central nervous system involvement. J. Gen. Virol. 2004;85:69–77. doi: 10.1099/vir.0.19423-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.19423-0</ArticleId><ArticleId IdType="pubmed">14718621</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingel K., Kandolf R. The role of enterovirus replication in the development of acute and chronic heart muscle disease in different immunocompetent mouse strains. Scand. J. Infect. Dis. Suppl. 1993;88:79–85.</Citation><ArticleIdList><ArticleId IdType="pubmed">8390720</ArticleId></ArticleIdList></Reference><Reference><Citation>Castello A., Alvarez E., Carrasco L. Differential cleavage of eIF4GI and eIF4GII in mammalian cells. Effects on translation. J. Biol. Chem. 2006;281:33206–33216. doi: 10.1074/jbc.M604340200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M604340200</ArticleId><ArticleId IdType="pubmed">16959778</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamud Y., Fu C., Fan Y.M., Zhang Y.L., Lin J.F.C., Hwang S.W., Wang Z.C., Luo H. Activation of cGAS-STING suppresses coxsackievirus replication via interferon-dependent signaling. Antiviral Res. 2024;222:105811. doi: 10.1016/j.antiviral.2024.105811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2024.105811</ArticleId><ArticleId IdType="pubmed">38242503</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>